Cargando…
Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino‐terminal domain
Prostate cancer (PCa) often recurs as incurable castration‐resistant prostate cancer (CRPC) after the failure of androgen deprivation therapy. CRPC development relies on androgen receptor (AR) signaling. The IL6/STAT3 pathway is also a key driver of CRPC. The crosstalk between IL6/STAT3 and the AR p...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218398/ https://www.ncbi.nlm.nih.gov/pubmed/30410767 http://dx.doi.org/10.1002/prp2.437 |
_version_ | 1783368440019419136 |
---|---|
author | Hua, Yaping Azeem, Waqas Shen, Yunheng Zhang, Shoude Olsen, Jan R. Øyan, Anne M. Ke, Xisong Zhang, Weidong Kalland, Karl‐Henning |
author_facet | Hua, Yaping Azeem, Waqas Shen, Yunheng Zhang, Shoude Olsen, Jan R. Øyan, Anne M. Ke, Xisong Zhang, Weidong Kalland, Karl‐Henning |
author_sort | Hua, Yaping |
collection | PubMed |
description | Prostate cancer (PCa) often recurs as incurable castration‐resistant prostate cancer (CRPC) after the failure of androgen deprivation therapy. CRPC development relies on androgen receptor (AR) signaling. The IL6/STAT3 pathway is also a key driver of CRPC. The crosstalk between IL6/STAT3 and the AR pathways provides opportunities to explore next‐generation agents to treat PCa. Through screening of around 600 natural compounds in our newly established prostate tumorigenesis model, potential STAT3 signaling inhibitors were found and additionally examined for effects on AR signaling. The small molecular compound 154 exhibited dual effects on IL6/STAT3 and AR pathways. We show here that compound 154 inhibits AR and STAT3 transcriptional activity, reduces the expression of phosphorylation of STAT3 (Y705) and downregulates the mRNA levels of AR target genes. Compound 154 also inhibits protein expression of AR and AR splice variants (ARv567es and AR‐V7) without altering AR mRNA levels. Compound 154 binds to AR directly, but not to STAT3 and is identified as an antagonist of the AR amino‐terminal domain (NTD) by disrupting protein‐protein interactions between STAT3 and the AR NTD. Moreover, compound 154 does not reduce AR nuclear translocation. Compound 154 possesses the potential to become a leading compound in novel therapies against CRPC. |
format | Online Article Text |
id | pubmed-6218398 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-62183982018-11-08 Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino‐terminal domain Hua, Yaping Azeem, Waqas Shen, Yunheng Zhang, Shoude Olsen, Jan R. Øyan, Anne M. Ke, Xisong Zhang, Weidong Kalland, Karl‐Henning Pharmacol Res Perspect Original Articles Prostate cancer (PCa) often recurs as incurable castration‐resistant prostate cancer (CRPC) after the failure of androgen deprivation therapy. CRPC development relies on androgen receptor (AR) signaling. The IL6/STAT3 pathway is also a key driver of CRPC. The crosstalk between IL6/STAT3 and the AR pathways provides opportunities to explore next‐generation agents to treat PCa. Through screening of around 600 natural compounds in our newly established prostate tumorigenesis model, potential STAT3 signaling inhibitors were found and additionally examined for effects on AR signaling. The small molecular compound 154 exhibited dual effects on IL6/STAT3 and AR pathways. We show here that compound 154 inhibits AR and STAT3 transcriptional activity, reduces the expression of phosphorylation of STAT3 (Y705) and downregulates the mRNA levels of AR target genes. Compound 154 also inhibits protein expression of AR and AR splice variants (ARv567es and AR‐V7) without altering AR mRNA levels. Compound 154 binds to AR directly, but not to STAT3 and is identified as an antagonist of the AR amino‐terminal domain (NTD) by disrupting protein‐protein interactions between STAT3 and the AR NTD. Moreover, compound 154 does not reduce AR nuclear translocation. Compound 154 possesses the potential to become a leading compound in novel therapies against CRPC. John Wiley and Sons Inc. 2018-11-05 /pmc/articles/PMC6218398/ /pubmed/30410767 http://dx.doi.org/10.1002/prp2.437 Text en © 2018 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Hua, Yaping Azeem, Waqas Shen, Yunheng Zhang, Shoude Olsen, Jan R. Øyan, Anne M. Ke, Xisong Zhang, Weidong Kalland, Karl‐Henning Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino‐terminal domain |
title | Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino‐terminal domain |
title_full | Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino‐terminal domain |
title_fullStr | Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino‐terminal domain |
title_full_unstemmed | Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino‐terminal domain |
title_short | Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino‐terminal domain |
title_sort | dual androgen receptor (ar) and stat3 inhibition by a compound targeting the ar amino‐terminal domain |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218398/ https://www.ncbi.nlm.nih.gov/pubmed/30410767 http://dx.doi.org/10.1002/prp2.437 |
work_keys_str_mv | AT huayaping dualandrogenreceptorarandstat3inhibitionbyacompoundtargetingthearaminoterminaldomain AT azeemwaqas dualandrogenreceptorarandstat3inhibitionbyacompoundtargetingthearaminoterminaldomain AT shenyunheng dualandrogenreceptorarandstat3inhibitionbyacompoundtargetingthearaminoterminaldomain AT zhangshoude dualandrogenreceptorarandstat3inhibitionbyacompoundtargetingthearaminoterminaldomain AT olsenjanr dualandrogenreceptorarandstat3inhibitionbyacompoundtargetingthearaminoterminaldomain AT øyanannem dualandrogenreceptorarandstat3inhibitionbyacompoundtargetingthearaminoterminaldomain AT kexisong dualandrogenreceptorarandstat3inhibitionbyacompoundtargetingthearaminoterminaldomain AT zhangweidong dualandrogenreceptorarandstat3inhibitionbyacompoundtargetingthearaminoterminaldomain AT kallandkarlhenning dualandrogenreceptorarandstat3inhibitionbyacompoundtargetingthearaminoterminaldomain |